GE HealthCare Tech

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, with revenue of $5,295M (+0.69% vs. consensus) and Adjusted EPS of $1.13 (+9.08% vs. consensus). Growth was primarily driven by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), which offset a 13.3% decline in Patient Care Solutions (PCS). Management reaffirmed FY26 guidance but signaled ongoing inflation headwinds of ~$250M, while record organic orders growth of 11.1% provides strong visibility for future quarters.